Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar-Apr;16(2):192-207.
doi: 10.1097/ADM.0000000000000863.

Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws

Barbara Andraka-Christou  1 , Adam J Gordon, Kathryn Bouskill, Rosanna Smart, Olivia Randall-Kosich, Matthew Golan, Rachel Totaram, Bradley D Stein
Affiliations
Review

Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws

Barbara Andraka-Christou et al. J Addict Med. 2022 Mar-Apr.

Abstract

Objectives: Buprenorphine is a gold standard treatment for opioid use disorder (OUD). Some US states have passed laws regulating office-based buprenorphine treatment (OBBT) for OUD, with requirements beyond those required in federal law. We sought to identify themes in state OBBT laws.

Methods: Using search terms related to medications for OUD, we searched Westlaw software for state regulations and statutes in 51 US jurisdictions from 2005 to 2019. We identified and inductively analyzed OBBT laws for themes.

Results: Since 2005, 10 states have passed a total of 181 OBBT laws. We identified the following themes: (1) provider credentials: state licensure for OBBT providers and continuing medical education requirements; (2) new patients: objective symptoms patients must have before receiving OBBT and exceptions for special populations; (3) educating patients: general informed consent requirements, and specific information to provide; (4) counseling: minimum counselor credentials, minimum counseling frequency, counseling alternatives; (5) patient monitoring: required prescription drug monitoring checks, frequency of drug screening, and responses to lost/stolen medications; (6) enhanced clinician monitoring: evidence-based treatment protocols, minimum clinician-patient contact frequency, health assessment requirements, and individualized treatment planning; and (7) patient safety: reconciling prescriptions, dosage limitations, naloxone coprescribing, tapering, and office closures.

Conclusions: Some laws codify practices for which scientific consensus is lacking. Additionally, some OBBT laws resemble opioid treatment programs and pain management regulations. Results could serve as the basis for a typology of office-based treatment laws, which could facilitate empirical examination of policy impacts on treatment access and quality.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1:
Figure 1:
Search process
Figure 2:
Figure 2:
Office-Based Buprenorphine Treatment Common Policy Themes & Subthemes
See this image and copyright information in PMC

Comment in

References

    1. Saha TD, Kerridge BT, Goldstein RB, et al. Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States. J Clin Psychiatry. 2016;77(6):772–780. - PMC - PubMed
    1. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder TIP 63 Treatment Improvement Protocol For Healthcare and Addiction Professionals, Policymakers, Patients, and Families. Subtance Abuse & Mental Health Services Administration;2018.
    1. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622. - PMC - PubMed
    1. Larochelle MR, Bernson D, Land T, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Annals of Internal Medicine. 2018;169(3):137–145. - PMC - PubMed
    1. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical research ed). 2017;357:j1550. - PMC - PubMed

Publication types

MeSH terms